- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INNOVATION PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,870 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 7,239 | -0,75 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,990 | 0,00 % | Heidelberg Pharma erhält Rückenwind von der FDA | Die US-Zulassungsbehörde macht Tempo. Heidelberg Pharma (ISIN DE000A11QVV0) hat für seinen Wirkstoffkandidaten HDP-101 den Fast-Track-Status von der FDA erhalten. Das ist mehr als nur ein bürokratischer... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,120 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,630 | +4,28 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 21,270 | +2,16 % | A Peek at Sarepta Therapeutics' Future Earnings | ||
| EXELIXIS | 34,130 | +1,76 % | Exelixis Q2 2025: Cabozantinib-Franchise wächst um 19 %, Markteinführung bei NET gewinnt an Fahrt | ||
| VAXART | 0,327 | +20,07 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| GERON | 1,109 | +1,93 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,320 | -2,22 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,182 | +1,16 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| MICROBOT MEDICAL | 1,962 | +1,29 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,390 | +2,57 % | FDA-Sonderstatus für Krebstherapie beflügelt Cellectar-Aktie |
Das Unternehmen INNOVATION PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNOVATION PHARMACEUTICALS INC finden Sie auf Wallstreet Online.